If you could vote on Brexit now which option would you choose?
   

GlaxoSmithKline, CureVac and BioNTech clinch German pandemic preparedness contracts


As CureVac and GlaxoSmithKline mulligan with a second-generation COVID-19 vaccine, the partners have signed on for a German pandemic contingency plan to earmark mRNA production capacity for years to come. The contract with the German federal government will see GSK and CureVac supply mRNA vaccines “within a broader tender for pandemic preparedness in Germany.' After a maximum two-year setup period, the companies will provide the German government with access to CureVac’s manufacturing capacity until 2029. Under the deal, CureVac and GSK will be able to swiftly deploy 80 million mRNA shot doses annually “during the remainder of the current pandemic or in future infectious disease outbreaks,” the partners said in a release Monday. The move seeks to counter the sort of supply bottlenecks that were commonplace in the pandemic’s early days, the partners added. With GSK and Curevac’s mRNA muscle on retainer, Germany will pay the partners an annual standby fee, following successful setup, which entails maintaining production capacity “at constant readiness.”

FiercePharma - April 11, 2022

View the full story here: https://www.fiercepharma.com/pharma/glaxosmithkline-and-curevac-clinch-contract-earmark-german-mrna-vaccine-capacity-years-come